Viewing the Impact of the Collective Departure of Pfizer's Five Executives on the Operations of Non-PatentEd Pharmaceuticals

Late at night, after receiving explosive news, all five general managers of Pfizer leftIf not mistakenly, this should be the first time in recent years pharmaceutical companies all-business general manager departure, Pfizer is worthy of the cosmopharma, even organizational changes are unique, differentAfter4 plus 7, companies are looking for ways to deal with Pfizer announced the creation of Pfizer4 plus 7 expansion, this wave is no longer a pilot, the formation of the national collection model, laid the Chinese pharmaceutical ecological pattern, innovation and imitation is the future of pharmaceutical enterprises, as a can control the ever-changing Pfizer, once again let the world "surprise", Pfizer will form a new generic group with Mylan, Mylanpuqiangwolf is really here, are you ready?On May 2, 2018, DrWu joined Baiji Shenzhou as General Manager and President of China, leaving Pfizer, which has been with pfizer for 15 yearsOn September 10, 2019, Michael Goettler, global president of Pfizer Group, announced to employees that Frank Wu, Pfizer's leader, would step down to pursue other career opportunities, as an industry leader, leaving the world's leading 100-year-old pharmaceutical company, what is the intention? Is it just a career bottleneck, or is it a more challenging opportunity?in the author's view, as the industry's top big curry the most important ability is to predict, the industry, the future of the prediction, any choice is an in-depth analysis, the future after the forecast mature decision-makingthe development of China's pharmaceutical market, more convergence between the European and American markets, and gradually move towards norms and orderDrWu joined the global innovative pharmaceutical companies because of his early overseas experience and his professional height, predicting the dramatic changes in the Chinese pharmaceutical marketFrank.Wu, as the leader of facing the 4 plus 7, led Puqiang to deal with the profound changes in the pharmaceutical market, and was helpless to meet the 4 plus 7 expansionbig man has big man problems, small people have the trouble of small people, in fact, the two problems encountered, but also millions of Chinese medical practitioners face problemsChina's pharmaceutical pattern will no longer be a dispute between state-owned enterprises and foreign enterprises, but a dispute between patented drugs and non-patented pharmaceutical enterprises
with the deepening of China's medical reform, from research and development, production, circulation, marketing and other aspects of continuous improvement, to help the Chinese pharmaceutical field to quickly and international standards, to promote the transformation and upgrading of Chinese pharmaceutical enterprises in the past, foreign-funded pharmaceutical enterprises expired patent original research drugs in the domestic has been enjoying the level of treatment of patented drugs, pricing and policies are superior to domestic drugs And domestic pharmaceutical companies are only in the extensive operation, do not need precision strategy can also be sustained But with the industry in the policy changes, local pharmaceutical companies gradually explore the progress, quietly rise the spirit of the 19th Congress" to deepen the reform of the medical and health system, comprehensively establish the basic medical and health system with Chinese characteristics, the medical security system and the high-quality and efficient medical and health service system, and improve the modern hospital management system "Medical reform in 18 years of rapid progress, from the medical, pharmaceutical, medical and other three aspects of the formation of a joint effortto accelerate the policy landing, promote the upgrading and transformation of pharmaceutical enterprises In the future, the competitive pattern of Chinese medicine will undergo major changes, and gradually form the competitive pattern of patented and non-patented medicines, and gradually converge with the pattern of pharmaceutical industry in developed countries For example, the U.S patent drug and non-patentdrug ratio of 8:2, and the quantity ratio of 2:8, generic companies will cover a broader patient base, but the market share is not large the future of generic drug enterprises need to be leaned into the 1 Generic pharmaceutical enterprises face the trend of layoffs on behalf of pharmaceutical representatives
China's generic drug enterprises should always have Chinese characteristics and protected by China's national conditions, generic drugs high prices, uneven quality, but still sell well With the establishment of the 4 plus 7-expansion national collection model, the future generic drug promotion model will converge with Europe and the United States, pharmaceutical representatives will be sharply reduced The loudest sentence of this collection called "7 cents ammonia chlorpyrifos can be able to afford to do clinical promotion on behalf of the representative?" there is no doubt that generic companies will certainly adopt a low-cost operation In other words, the factor sepriority in the recruitment of pharmaceutical sales staff is no longer a profession, but the best price/performance ratio Such a merger would significantly reduce Pfizer's previous high labor costs, making them in line with generic drug companies medical representatives need to do career planning in advance, the next 20-30 years, how to plan their career? How to reinvent your career value sales managers will also be gradually reduced
once the clinical representative slashed, it is bound to be in the sales chain at all levels of managers will be reduced accordingly In the Pfizer announcement, there is a line that "The purpose of the structure adjustment of Puqiang's China business team is to adapt to changes in the Chinese market environment and to create a more efficient and flat management model." "As a result, in the future, generic drug enterprise organizations are bound to be simpler and more flat, and the resulting business model will be simple and fast." But there is still no trend in regional mergers from Pfizer's new architecture ask, the representative sat out, need to use the manager? After all, you can save hundreds of thousands of dollars a year 3 The marketing department from business-driven to service transformation generic pharmaceutical enterprises due to a sharp decline in the sales force, in fact, the function or importance of the marketing department is increased Especially for the current reduction of pharmaceutical representation, the need to use a lower cost, faster and simpler way to cover doctors, multi-channel MCM promotion will be popular in the future generic drug companies Get feedback with a third-party platform that reaches more doctors with personalized programs MCM marketing for generic pharmaceutical companies will also drive the digital impact level of the pharmaceutical industry marketing staff will also be significantly reduced It is likely that a company has multiple business units but only one MD, each product manager is responsible for the management of multiple brands, from the functional is no longer business-driven, more to the first-line business or clinician's service, which is a bit like the agency enterprise's marketing department operating model 4 Medical affairs will also converge in the functions of the marketing department, service support, but also accompanied by the reduction of staff the value of medicine in pharmaceutical enterprises is unquestionable, before the listing, whether or not, is post-market medical affairs also give important contributions to the life cycle management of enterprise products Good medical affairs, constantly enrich the clinical value of products, multi-dimensional, multi-angle medical research, and even carry out some research can increase or change the indications, which is very valuable, the future value of the department of generic pharmaceutical companies by the life cycle of patented drugs, it is not possible to do much But also can not generalize, many old medicine revitalised spring is the magic of medicine back to spring should last be business and government affairs, which communicate quotes and maintain relationships with the collection office, and ensure that companies get first-hand government information if we reduce staff, our way out
1 Transformation to the industry (1) upward transformation: conditional transfer to the pharmaceutical industry chain upstream, such as research and development, clinical and BD, with the fierce competition, the future of pharmaceutical enterprises in the upstream competition (2) Cross-enterprise transformation: the relationship between people can be transferred from the representative of a foreign enterprise to the domestic enterprise marketing department or the medical department 2 Turn to other similar industries
such as foreign insurance companies Insurance and pharmaceutical sales have a lot of convergence, large companies atmosphere, good welfare, good treatment, therefore, a lot of friends have turned to foreign insurance companies the way to win for generic companies
1 Reducing operating costs is a long-term need for enterprises to pay attention to the strategy reduce labor costs, is the enterprise to increase efficiency of the conventional method You can quickly reduce operating costs by laying off people and represent better profits in your financial statements At the same time, when the function of the future position is set up, recruit more cost-effective employees, do not envisage the existing staff pay cuts, which will be detrimental to the long-term organizational development of the enterprise Fortunately, layoffs are not the only way to reduce labor costs, and companies can consider shorter hours, vacations, and performance pay as an alternative to layoffs." simplify the organization's structure to make it flatter, improving organizational efficiency For now, pharmaceutical companies are making their organizations flatter, with fewer jobs and more jobs done in the past Pfizer, for example, has taken the lead in flattening its organization, flattening non-business units by 2018, moving teams with fewer than seven people on the line promote waste reduction, is the enterprise's ability to operate a greater embodiment More standardized enterprises are reduced to varying degrees or avoid waste, such as reducing unnecessary travel trips, reducing the complexity of work procedures, so as to establish an efficient and high-quality enterprise work culture Of course, this part requires a lot of effort in the business operations department, rather than imposing regulations and constraints, habits and culture is not a short-term outcome, need long-term persistence To cite a small example: some enterprises upgrade printing paper management, employees with employee cards in the printer swipe printing, operating departments based on the number of personal printing analysis, such a move compared with the previous unmanaged, saving paper usage, avoidunnecessary waste 2 Increase the layout of expired patents
early layout, and establish a priority strategy for research and development In foreign countries with 100 years of history of multinational enterprises, no pair of research and development are very important In particular, generic pharmaceutical companies need to understand the research and development layout of innovative pharmaceutical companies as early as possible in order to obtain the patent expiration of their innovative drugs and future sales forecasts optimize the portfolio strategy to make the strong "The portfolio strategy is important, which is more demanding for the strategic planning department of the firm, where the firm starts and matches the firm's own strengths to accommodate changes in the environment and between competitors." For example, Roche early on in strengthening its tumor development strategy, become familiar with the "anti-cancer brother", early years well-known brands such as Rochefen has become history respond to national policies and keep pace with national industrial strategies In all countries the development of pharmaceutical industry is related to the national economy and people's livelihood, is an important industry related to the national economy, so it is necessary for enterprises to pay attention to the changes in national strategies and understand policy orientation For example, in the process of establishing the national basic drug system, China has some drug shortages and can not meet the fundamental concept of "preserving basic" , so the Health and Reform Commission issued a list of shortage drugs, generic drugs, set up a platform for consultation, to encourage enterprises and the national industrial strategy in line with the pace 3 Seeking joint ventures or mergers and acquisitions is also a powerful way for many generic pharmaceutical companies to win
and the major enterprises are actively expanding Their BD business or carrying out overseas mergers and acquisitions in order to seek access to broader overseas resources and thus enrich their own product lines The main reason is that foreign research and development institutions and research and development enterprises early development, but also do not have the ability to expand globally, so in the main markets are looking for partners to expand product sales channels joint ventures with foreign companies to expand the international market Recently, a number of enterprises and Indian generic pharmaceutical joint ventures, the future with India's experience and channels in the field of global generic drugs, the most rapid chinese enterprises understand the rules of international competition, so as to enter the international market more quickly But this part also needs to be fully demonstrated, in the past several Chinese and pharmaceutical giants joint venture pharmaceutical companies, the desire to enter the international market has not been realized meet the door of China's medical reform, we are difficult, but also lucky It's too hard for us because change is so fast that we never experience it We are lucky because we will stay with the elite.